Meeting
2021 ASCO Annual Meeting
Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).
Authors
Thiago Pimentel Muniz
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
Thiago Pimentel Muniz , Daniel Vilarim Araujo , Kerry J. Savage , Tina Cheng , Moumita Saha , Xinni Song , Sabrina Gill , Jose Gerard Monzon , Debjani Grenier , Sofia Genta , Anna Spreafico , David Hogg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2640)
DOI
10.1200/JCO.2021.39.15_suppl.2640
Abstract #
2640
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
BMC128: A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors.
First Author: Corinne Maurice-Dror
Poster
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
First Author: Jordan Kardos
Poster
2023 ASCO Annual Meeting
Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma.
First Author: Sharjeel Syed
Poster
2022 ASCO Quality Care Symposium
Duration of first-line immune checkpoint inhibitor treatment in U.S. patients with melanoma, non–small cell lung cancer, and renal cell carcinoma.
First Author: Alia Rawji